Hager Gundel
The NCD Company, Polling, Germany.
Methods Mol Biol. 2024;2786:365-386. doi: 10.1007/978-1-0716-3770-8_17.
In this chapter, we will first consider the overall goal of nonclinical safety testing during drug development and have a brief overview of its regulatory background. We will then discuss some basic requirements of safety/toxicity testing before concentrating on the safety testing of RNA vaccines and developing a sample RNA vaccine safety testing program.